The COBRRA randomized trial that compared direct oral anticoagulants (DOACs) for acute venous thromboembolism (VTE), and ...
Venous thromboembolism includes deep vein thrombosis (DVT) and pulmonary embolism, which have incidence rates of between 1 and 2 cases per 1000 people for the first episode.1,2 Strong, provoking risk ...
In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.
Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.
March 13 () - A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of dangerous ...
A trial directly comparing Eliquis and Xarelto - two commonly used blood-thinning drugs from the same class of medicines - found that Eliquis carries a clearly lower risk of dangerous bleeding in ...
The first clinical trial to compare two commonly used drugs head-to-head for venous thrombosis treatment has found a clear ...
Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...
Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...
The COBRRA trial directly tested apixaban and rivaroxaban, the oral anticoagulants most frequently used to treat acute venous thromboembolism. The risk of clinically relevant bleeding came out ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results